A drug reimportation bill that would enable consumers, drug retailers, and wholesalers to import cheaper foreign drugs from FDA-approved plants and warehouses continues to gain support. The CBO reported that the bill would generate $50 billion in savings for pharmaceutical purchasers over 10 years.
While a floor vote has not yet been scheduled in either house, we continue to believe this, or a similar drug reimportation bill, will pass both houses in this Congress.
The real question is can its supporters sustain a Bush veto? That one is too close to call.